Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02139163

Epidemiological Study on Community Acquired Pneumonia

The main objective of this study is to investigate prevalence and risk factors for community-acquired pneumonia (CAP) and its interaction with comorbidities in an unselected group of adult patients receiving outpatient and inpatient care. In addition, information on HIV as a risk factor for CAP and on CAP in immunocompromised patients is collected.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The CAPNETZ study is a prospective, multicenter observational study investigating community-acquired pneumonia (CAP). Patients are recruited from outpatient and inpatient settings at hospitals and from primary care physicians (primarily specialists) and are followed for a period of six months. All CAP patients who meet the inclusion and exclusion criteria, consent to participate, and in whom the presence of a newly developed, community-acquired pneumonia can be verified are invited to participate. The baseline examination includes a detailed medical history, medication history, and a physical examination to record clinical and vital signs. In addition, the results of routine clinical imaging are documented, and biosamples (blood, urine, and respiratory specimens) are collected for clinical chemistry and microbiological analysis. Further in-person visits to document the course of the disease and treatment, including the collection of additional blood samples, take place 3 and 7 days after study enrollment. Twenty-eight days after enrollment, the patient's health status, treatment course, and complications are assessed by telephone. Finally, after 180 days, a telephone survey is conducted to determine the patient's whereabouts and survival status. Apart from the collection of biomaterials, no interventions are required or planned; physicians treat their patients as they normally would.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age ≥ 18
  • infiltrate on chest X-ray
  • further Inclusion criteria (at least one must apply): cough or purulent sputum or pathologic lung auscultation (crackles) or fever

Exclusion criteria

  • Hospitalization lasting longer than 48 hours prior to the diagnosis of the current pneumonia
  • Newly diagnosed, active pulmonary tuberculosis within the last 2 months

Treatment and study plan

Primary outcomes

  1. diagnosis

    Time frame: 2 weeks

    Assessment of diagnosis:

    Patients will be asked for example, about their diagnosis, comorbidities, specific risk factors and pneumonia symptoms.

  2. therapy

    Time frame: 2 weeks

    Assessment of therapy:

    Patients will be asked about their therapy due to pneumonia symptoms, previous therapy, medication History etc.

  3. hospitalization

    Time frame: 2 weeks

    Assessment of hospitalization:

    Patients will be asked about hospitalization, date, time and duration of hospitalization due to pneumonia symptoms.

Study contacts

Contact information is provided by the study sponsor or research team.

Frank Eberhardt

CONTACT

[email protected]

+49-511-532-5927

Waldemar Kröner

CONTACT

[email protected]

+49-511-532-4447

Sponsors and collaborators

Lead sponsor

Capnetz Stiftung

Other

Collaborators

  • Deutsches Zentrum für Lungenforschung e. V.

Registry information

Acronym: CAPNETZ

Important dates

Study start
2002
Primary completion
2027
Study completion
2028
First posted
May 15, 2014
Registry last updated
May 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.